Evaluation of the Gastro-intestinal Tolerance, Nutritional Intake, and Acceptability of an Upgraded Composition of an Enteral Tube Feed for Adults in Need of Long Term Nutritional Support (Peacock Butterfly)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Enteral Tube Nutrition
- Sponsor
- Nutricia Research
- Enrollment
- 101
- Locations
- 1
- Primary Endpoint
- Gastro-intestinal tolerance
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
This study evaluates the gastro-intestinal tolerance, nutritional intake, and acceptability of an upgraded composition of an enteral tube feed for adults in need of long term nutritional support.
Detailed Description
Four current tube feed products are upgraded with the same product composition and will be investigated in this study. Subjects will be asked to continue with their current tube feeding for 7 days (baseline period) and asked to complete a daily gastro-intestinal tolerance questionnaire. On Day 8, the subjects will switch to one of four upgraded tube feeding products for 14 days (intervention period). The subjects are asked to complete the same gastro-intestinal tolerance questionnaire for again 7 days. On Day 21 (end of intervention), the subjects will return to their original tube feed product and the investigator will follow up on how they are feeling to evaluate tolerability and product acceptability.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age ≥ 18 years
- •Using either an enteral tube feed with approximately 1.0 or 1.5 kcal/mL with or without fibers via a nasogastric tube (NGT), nasojejunal (NJT) or Percutaneous Endoscopic Gastrostomy (PEG) for at least 4 weeks prior to screening
- •Actual and expected average daily intake of enteral nutrition at least 1000 kcal for at least 21 days after the start of baseline period
- •Written informed consent from subject (or impartial witness after verbal consent of subject)
Exclusion Criteria
- •Subjects receiving total parental feeding (TPN)
- •Gastro-intestinal surgery or any other surgery involving general anaesthesia within 2 weeks prior to screening
- •Subjects with major hepatic or renal dysfunction in the opinion of the Investigator
- •Subjects currently in the intensive care unit
- •Active/flare up condition of chronic illnesses in small or large intestines in the opinion of the Investigator (e.g., active inflammation/flare up of Crohn's disease or ulcerative colitis) within 2 weeks prior to screening,
- •Subjects experiencing cancer treatment-related diarrhea within 2 weeks prior to screening
- •Presence of colostomy or other faecal diversion
- •Known intolerance or allergy to ingredients of study product (e.g. galactosemia, allergy to soy)
- •Inability of the subject to answer the study diary or questionnaires due to e.g., being unconscious, cognitive impairment, or dementia, in the opinion of the Investigator
- •Known pregnancy or lactation
Outcomes
Primary Outcomes
Gastro-intestinal tolerance
Time Frame: 7 days in the second week of the 2-week intervention period
self-reported GI symptoms with a GI symptom questionnaire
bowel movement pattern
Time Frame: 7 days in the second week of the 2-week intervention period
Self reported bowel movement pattern with the 7-point Bristol Stool Form Scale (BSFS) ranging from "1" (indicating separate, hard lumps) to "7", which stands for entirely liquid, watery stool without any hard components
Secondary Outcomes
- Use of complementary feeding with a questionnaire ((use of normal foods, oral nutritional supplements, parenteral feeding: Yes/No)(7 days in the 1-week baseline period, 7 days in the first week of the 2-week intervention period, and 7 days in the second week of the 2-week intervention period (i.e., on a daily basis during the entire study duration).)
- Volume of tube feed administration(7 days in the 1-week baseline period, 7 days in the first week of the 2-week intervention period, and 7 days in the second week of the 2-week intervention period (i.e., on a daily basis during the entire study duration).)
- Difference between prescribed volume of tube feed administration by Health Care Professional and actual daily self-reported administrated volume of tube feed(7 days in the 1-week baseline period, 7 days in the first week of the 2-week intervention period, and 7 days in the second week of the 2-week intervention period (i.e., on a daily basis during the entire study duration).)
- Product acceptability with a questionnaire(Day 21 (end of intervention period regarding the upgraded tube feed))
- Anthropometrics(Intervention Day 21)